Clinical trial
A Single-arm Phase II Study of Chemoradiotherapy Plus Pembrolizumab as Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Patients at High Risk of Recurrence Following Preoperative Chemoradiotherapy Plus Surgery
NCT03322267 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm Phase II Study of Chemoradiotherapy Plus Pembrolizumab as Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Patients at High Risk of Recurrence Following Preoperative Chemoradiotherapy Plus Surgery
- Lead sponsor
- National Taiwan University Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 27, 2018
- Completion date
- January 30, 2026
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.